TY - JOUR
T1 - Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains
AU - Wen, X.
AU - Wu, Q. P.
AU - Lu, Y.
AU - Fan, Z.
AU - Charnsangavej, C.
AU - Wallace, S.
AU - Chow, D.
AU - Li, C.
PY - 2001
Y1 - 2001
N2 - Several biological barriers, including significant liver uptake, limit the clinical application of radiolabeled antibodies in radioimmunoscintigraphy. Here, a general approach is described for radiolabeling of monoclonal antibodies conjugated with poly(ethylene glycol) (PEG). This strategy is demonstrated with C225, a monoclonal antibody directed against epidermal growth factor (EGF) receptor. We synthesized a heterofunctional PEG with one end attached to a radiometal chelator, diethylenetriaminepentaacetic acid (DTPA), and the other end to a protected thiol group, S-acetylthioacetate. After a deprotection step, the resulting DTPA-PEG-SH was conjugated to maleimide-activated C225 to yield DTPA-PEG-C225 conjugate. Characterization of DTPA-PEG-C225 with immunoprecipitation and Western blot analysis revealed that the conjugate was biologically active in binding to the EGF receptor in A431 cells. Competitive EGF receptor binding assay in MDA-MB-468 cells showed that DTPA-PEG-C225, with up to 60% of the amino groups in C225 substituted, retained 66% of C225's binding affinity. Moreover, DTPA-PEG-C225 with increasing degrees of NH2 substitution from 20% to 70% retained the activity of C225 to induce apoptosis in DiFi cells. More importantly, DTPA-PEG-C225 demonstrated less nonspecific interaction than DTPA-C225. Pharmacokinetic analysis using 111In-labeled compounds revealed narrower steady-state distribution of 111In-DTPA-PEG-C225 than 111In-DTPA-C225, probably due to reduced nonspecific binding of PEG-modified antibody to tissues. The terminal half-life (t1/2,γ) of 111In-DTPA-PEG-C225, 21.1 h, was shorter than that of 111In-DTPA-C225, 52.9 h. These data suggest that 111In-DTPA-PEG-C225 may provide better imaging characteristics than 111In-DTPA-C225, and that using PEG as a linker between the monoclonal antibody and DTPA may be a promising strategy in optimizing the imaging characteristics of immunoscintigraphic agents.
AB - Several biological barriers, including significant liver uptake, limit the clinical application of radiolabeled antibodies in radioimmunoscintigraphy. Here, a general approach is described for radiolabeling of monoclonal antibodies conjugated with poly(ethylene glycol) (PEG). This strategy is demonstrated with C225, a monoclonal antibody directed against epidermal growth factor (EGF) receptor. We synthesized a heterofunctional PEG with one end attached to a radiometal chelator, diethylenetriaminepentaacetic acid (DTPA), and the other end to a protected thiol group, S-acetylthioacetate. After a deprotection step, the resulting DTPA-PEG-SH was conjugated to maleimide-activated C225 to yield DTPA-PEG-C225 conjugate. Characterization of DTPA-PEG-C225 with immunoprecipitation and Western blot analysis revealed that the conjugate was biologically active in binding to the EGF receptor in A431 cells. Competitive EGF receptor binding assay in MDA-MB-468 cells showed that DTPA-PEG-C225, with up to 60% of the amino groups in C225 substituted, retained 66% of C225's binding affinity. Moreover, DTPA-PEG-C225 with increasing degrees of NH2 substitution from 20% to 70% retained the activity of C225 to induce apoptosis in DiFi cells. More importantly, DTPA-PEG-C225 demonstrated less nonspecific interaction than DTPA-C225. Pharmacokinetic analysis using 111In-labeled compounds revealed narrower steady-state distribution of 111In-DTPA-PEG-C225 than 111In-DTPA-C225, probably due to reduced nonspecific binding of PEG-modified antibody to tissues. The terminal half-life (t1/2,γ) of 111In-DTPA-PEG-C225, 21.1 h, was shorter than that of 111In-DTPA-C225, 52.9 h. These data suggest that 111In-DTPA-PEG-C225 may provide better imaging characteristics than 111In-DTPA-C225, and that using PEG as a linker between the monoclonal antibody and DTPA may be a promising strategy in optimizing the imaging characteristics of immunoscintigraphic agents.
UR - http://www.scopus.com/inward/record.url?scp=0034920906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034920906&partnerID=8YFLogxK
U2 - 10.1021/bc0001443
DO - 10.1021/bc0001443
M3 - Article
C2 - 11459459
AN - SCOPUS:0034920906
SN - 1043-1802
VL - 12
SP - 545
EP - 553
JO - Bioconjugate Chemistry
JF - Bioconjugate Chemistry
IS - 4
ER -